These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29435052)

  • 21. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
    Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
    Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
    Zhong T; Xu F; Xu J; Liu L; Chen Y
    Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. siAKR1C3@PPA complex nucleic acid nanoparticles inhibit castration-resistant prostate cancer in vitro.
    Cui X; Yao Z; Zhao T; Guo J; Ding J; Zhang S; Liang Z; Wei Z; Zoa A; Tian Y; Li J
    Front Oncol; 2022; 12():1069033. PubMed ID: 36591491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
    Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
    Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consecutive Prostate Cancer Specimens Revealed Increased Aldo⁻Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer.
    Miyazaki Y; Teramoto Y; Shibuya S; Goto T; Okasho K; Mizuno K; Uegaki M; Yoshikawa T; Akamatsu S; Kobayashi T; Ogawa O; Inoue T
    J Clin Med; 2019 May; 8(5):. PubMed ID: 31052459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-Androgen Abiraterone Acetate Improves the Therapeutic Efficacy of Statins on Castration-Resistant Prostate Cancer Cells.
    Miller DR; Ingersoll MA; Chou YW; Wakefield CB; Tu Y; Lin FF; Chaney WG; Lin MF
    J Oncol Res Ther; 2017; 3(5):. PubMed ID: 31328181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review.
    Karunasinghe N; Masters J; Flanagan JU; Ferguson LR
    Curr Cancer Drug Targets; 2017; 17(7):603-616. PubMed ID: 28359237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts.
    Gordon JA; Midha A; Szeitz A; Ghaffari M; Adomat HH; Guo Y; Klassen TL; Guns ES; Wasan KM; Cox ME
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):21-7. PubMed ID: 26238234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of castration-resistant prostate cancer growth by genistein through suppression of AKR1C3.
    Yu X; Yan J; Li Y; Cheng J; Zheng L; Fu T; Zhu Y
    Food Nutr Res; 2023; 67():. PubMed ID: 36794010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?
    Karunasinghe N; Zhu Y; Han DY; Lange K; Zhu S; Wang A; Ellett S; Masters J; Goudie M; Keogh J; Benjamin B; Holmes M; Ferguson LR
    BMC Urol; 2016 Aug; 16(1):48. PubMed ID: 27485119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, Synthesis and Cytotoxicity Evaluation of Novel Indole Derivatives Containing Benzoic Acid Group as Potential AKR1C3 Inhibitors.
    Sun M; Zhou Y; Zhuo X; Wang S; Jiang S; Peng Z; Kang K; Zheng X; Sun M
    Chem Biodivers; 2020 Dec; 17(12):e2000519. PubMed ID: 33111427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
    Doig CL; Battaglia S; Khanim FL; Bunce CM; Campbell MJ
    J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):47-55. PubMed ID: 26429394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.
    Miyake H; Nelson C; Rennie PS; Gleave ME
    Endocrinology; 2000 Jun; 141(6):2257-65. PubMed ID: 10830316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
    Wu CH; Ko JL; Chen SC; Lin YW; Han CP; Yang TY; Chien MH; Wang PH
    Gynecol Oncol; 2014 Feb; 132(2):474-82. PubMed ID: 24316309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
    Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines.
    Pennanen P; Syvälä H; Bläuer M; Savinainen K; Ylikomi T; Tammela TLJ; Murtola TJ
    Eur J Pharmacol; 2016 Oct; 788():160-167. PubMed ID: 27341997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model.
    Masko EM; Alfaqih MA; Solomon KR; Barry WT; Newgard CB; Muehlbauer MJ; Valilis NA; Phillips TE; Poulton SH; Freedland AR; Sun S; Dambal SK; Sanders SE; Macias E; Freeman MR; Dewhirst MW; Pizzo SV; Freedland SJ
    Prostate; 2017 Apr; 77(5):446-457. PubMed ID: 27900797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.